Quarterly Updates6 Nov 2025, 10:20 pm
Sai Life Sciences Reports 36% Revenue Growth in Q2FY26, 100% Net Profit Increase
AI Summary
Sai Life Sciences Limited, a leading Contract Research, Development and Manufacturing Organizations (CRDMO), announced its financial results for the second quarter and half year ended September 2025. The company reported a 36% increase in Revenue from Operations, a 43% rise in EBITDA, and a 100% jump in Net Profit for Q2FY26. The revenue for H1FY26 increased by 53%. The company also highlighted its expanded capabilities in new technologies and modalities, successful completion of audits, and partnerships.
Key Highlights
- Revenue from Operations increased by 36% in Q2FY26
- EBITDA rose by 43% in Q2FY26
- Net Profit doubled in Q2FY26
- Expanded capabilities in new technologies and modalities
- Successfully completed 35 customer and 3 regulatory audits in the past 12 months